GALECTIN THERAPEUTICS INC. (GALT) Debt Components
- 2021-09-30: Long-term Line of CreditUSD $0.00; Convertible Notes PayableUSD $10.00M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2021-06-30: Long-term Line of CreditUSD (m); Convertible Notes PayableUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure (m).
- 2021-04-16: Long-term Line of CreditUSD (m); Convertible Notes PayableUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Interest Rate, Stated Percentagepure 2.00%.
- 2019-01-31: Long-term Line of CreditUSD (m); Convertible Notes PayableUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD $10.00M; Debt Instrument, Interest Rate, Stated Percentagepure (m).
GALECTIN THERAPEUTICS INC. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Line of Credit USD | Convertible Notes Payable USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Interest Rate, Stated Percentage pure | Debt Instrument, Convertible, Conversion Price USD/shares | Debt Instrument, Increase, Accrued Interest USD |
|---|---|---|---|---|---|---|
| 2021-09-30 | $0.00 | $10.00M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | 6 month · $41.00K |
| 2021-04-16 | (m) | (m) | (m) | 2.00% | 5.00 | (m) |
| 2019-01-31 | (m) | (m) | $10.00M | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | 15.00% | (m) | (m) |
| 2001-08-31 | (m) | (m) | (m) | (m) | 12.00 | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |